Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib
Jikui Guan(Zhengzhou University), Bengt Hallberg(University of Gothenburg)
Cited by 48
Related Papers
Cell culture and<i>Drosophila</i>model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma
|Disease Models & Mechanisms|2012|60
Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways
|Science Signaling|2018|40
The Neuroblastoma ALK(I1250T) Mutation Is a Kinase-Dead RTK In Vitro and In Vivo
|Translational Oncology|2011|37